SCHEMBL21821314

SCHEMBL21821314

COCCNC(=O)CC(Nc1nc2ccccc2[nH]1)c1cccc(SC)c1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 9/20 0.47
▸ NPC1 O15118 8/20 0.47
▸ PKM P14618 2/20 0.47
▸ HSP90AA1 P07900 1/20 0.47
▸ HPGD P15428 1/20 0.44
▸ SMN1; SMN2 Q16637 7/20 0.43
▸ HTT P42858 1/20 0.43
▸ MEN1 O00255 2/20 0.42
▸ KMT2A Q03164 2/20 0.42
▸ LMNA P02545 3/20 0.41
▸ HSD17B10 Q99714 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ NTRK1 P04629 1/20 0.39
▸ NTRK2 Q16620 1/20 0.39
▸ ALDH1A1 P00352 2/20 0.39
▸ TP53 P04637 2/20 0.38
▸ ALOX12 P18054 1/20 0.38
▸ BCHE P06276 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19283684 0.90 HPGD (0.41) RAB9ANPC1PKMHSP90AA1HPGD
SCHEMBL21821298 0.88 HPGD (0.40) RAB9ANPC1PKMHSP90AA1HPGD
SCHEMBL30645121 0.86 NPC1 (0.48) RAB9ANPC1PKMHSP90AA1SMN1; SMN2
SCHEMBL20743189 0.86 NPC1 (0.48) RAB9ANPC1PKMHSP90AA1SMN1; SMN2
SCHEMBL19283561 0.85 ITGA5 (0.45) RAB9ANPC1PKMHPGDSMN1; SMN2
SCHEMBL19283672 0.84 MTOR (0.47) RAB9ANPC1PKMHPGDSMN1; SMN2
SCHEMBL19283571 0.83 HPGD (0.44) RAB9ANPC1PKMHSP90AA1HPGD
SCHEMBL19283595 0.81 NPC1 (0.39) RAB9ANPC1SMN1; SMN2HTTMEN1
SCHEMBL19283463 0.78 LMNA (0.48) RAB9ANPC1PKMSMN1; SMN2HTT
SCHEMBL21821306 0.77 NPC1 (0.42) RAB9ANPC1PKMSMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11274092-B2 Potassium channel inhibitors ACESION PHARMA APS (DK) 2022-03-15 — — US claimed
US-20210188804-A1 NOVEL POTASSIUM CHANNEL INHIBITORS ACESION PHARMA APS (DK) 2021-06-24 — — US claimed
CN-109153667-B Novel potassium channel inhibitors 阿塞西翁制药公司 2021-04-02 — — CN claimed
EP-3419973-B1 NOVEL POTASSIUM CHANNEL INHIBITORS ACESION PHARMA APS (DK) 2020-04-08 — — EP claimed
US-11274092-B2 Potassium channel inhibitors ACESION PHARMA APS (DK) 2022-03-15 — — US disclosed
US-20210188804-A1 NOVEL POTASSIUM CHANNEL INHIBITORS ACESION PHARMA APS (DK) 2021-06-24 — — US disclosed
US-20210188804-A1 NOVEL POTASSIUM CHANNEL INHIBITORS ACESION PHARMA APS (DK) 2021-06-24 — — US disclosed
CN-109153667-B Novel potassium channel inhibitors 阿塞西翁制药公司 2021-04-02 — — CN disclosed
EP-3419973-B1 NOVEL POTASSIUM CHANNEL INHIBITORS ACESION PHARMA APS (DK) 2020-04-08 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210188804-A1 NOVEL POTASSIUM CHANNEL INHIBITORS KCNJ2, KCNN2, KCNN1 RAB9A 1632/4885NPC1 277/4885PKM 292/4885
US-11274092-B2 Potassium channel inhibitors KCNJ2, KCNJ11, KCNJ1 RAB9A 1920/4885NPC1 268/4885PKM 243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback